Biosimilars
Regulatory
Mylan & Biocon Receive CHMP Recommendation to Ogivri (trastuzumab, biosimilar)
Shots: The CHMP recommendation will be reviewed by EU with expected closure in H2’18. In 2017, FDA approved Ogivri a novel biosimilar to Herceptin with additional regulatory approval in 35 […]readmore